Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct;18(15):1381-1386.
doi: 10.2217/pgs-2017-0137. Epub 2017 Oct 6.

Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai

Stuart A Scott  1   2   3 , Aniwaa Owusu Obeng  3   4 , Mariana R Botton  1   2 , Yao Yang  1   2   5 , Erick R Scott  1   2   5 , Stephen B Ellis  3 , Richard Wallsten  2 , Tom Kaszemacher  3 , Xiang Zhou  1   2   5 , Rong Chen  1   2   5 , Paola Nicoletti  1   2 , Hetanshi Naik  1 , Eimear E Kenny  1   3   5 , Aida Vega  6 , Eva Waite  6 , George A Diaz  1   2 , Joel Dudley  1   5   7 , Jonathan L Halperin  8 , Lisa Edelmann  1   2 , Andrew Kasarskis  1   5 , Jean-Sébastien Hulot  9   10 , Inga Peter  1   3 , Erwin P Bottinger  3   11 , Kurt Hirschhorn  1 , Pamela Sklar  1   5   12 , Judy H Cho  1   3   13 , Robert J Desnick  1   2 , Eric E Schadt  1   2   5
Affiliations
Review

Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai

Stuart A Scott et al. Pharmacogenomics. 2017 Oct.

Abstract

For almost 50 years, the Icahn School of Medicine at Mount Sinai has continually invested in genetics and genomics, facilitating a healthy ecosystem that provides widespread support for the ongoing programs in translational pharmacogenomics. These programs can be broadly cataloged into discovery, education, clinical implementation and testing, which are collaboratively accomplished by multiple departments, institutes, laboratories, companies and colleagues. Focus areas have included drug response association studies and allele discovery, multiethnic pharmacogenomics, personalized genotyping and survey-based education programs, pre-emptive clinical testing implementation and novel assay development. This overview summarizes the current state of translational pharmacogenomics at Mount Sinai, including a future outlook on the forthcoming expansions in overall support, research and clinical programs, genomic technology infrastructure and the participating faculty.

Keywords: Icahn School of Medicine at Mount Sinai; clinical implementation; discovery; education; genetic testing; pharmacogenetics; pharmacogenomics.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This work was supported in part by the National Institute of General Medical Sciences (NIGMS) of the NIH through grant K23GM104401 (SA Scott), and the National Human Genome Research Institute (NHGRI) of the NIH through grants U01HG008701-02S1 and U01HG006380 (eMERGE Network; EP Bottinger, AO Obeng) and U01HG007278 (IGNITE Network; EP Bottinger, AO Obeng). Funding for The Charles Bronfman Institute for Personalized Medicine was provided by the Andrea and Charles Bronfman Philanthropies and the Icahn School of Medicine at Mount Sinai. SA Scott, MR Botton, Y Yang, ER Scott, R Wallsten, X Zhou, R Chen, P Nicoletti, GA Diaz, L Edelmann, RJ Desnick and EE Schadt are paid employees or consultants of Sema4, which is a commercial company that offers clinical pharmacogenomic testing. EP Bottinger and SB Ellis are named co-inventors on a patent application and have developed software and know-how related to CLIPMERGE, a medical decision support software platform that collects, aggregates and displays clinical data. The platform allows for personalized medical decision making. The CLIPMERGE tool is being utilized in pharmacogenetics research described in this manuscript. The intellectual property related to the software and know-how has been licensed by the Icahn School of Medicine to Ontomics Inc, a privately held company in which EP Bottinger and SB Ellis are equity owners. If the CLIPMERGE technology is commercially successful, EP Bottinger and SB Ellis will benefit financially and, in addition, payments will be made to the Icahn School of Medicine as part of the license agreement. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai in New York City.
(A) Race and ethnicity of the New York City metropolitan area population based on data from census 2010. Each colored dot represents 25 residents: red is Caucasian, blue is African–American, green is Asian, orange is Hispanic and yellow is ‘other’. (B) An illustration of the translational pharmacogenomics programs at the Icahn School of Medicine at Mount Sinai, highlighting the academic and commercial entities in boxes, which in collaboration with clinical partners are jointly invested in pharmacogenomic discovery, education, clinical implementation, and technology and testing. (A) Adapted with permission from Eric Fischer: Race and Ethnicity 2010 - New York City (5559914315).png (© Eric Fischer, some rights reserved, CC BY-SA 2.0).
See this image and copyright information in PMC

References

    1. Hirschhorn K, Hirschhorn R. 2013 Victor A. McKusick Leadership Award addresses. Am. J. Hum. Genet. 2014;94(3):336–337. - PMC - PubMed
    1. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N. Engl. J. Med. 2001;345(1):9–16. - PubMed
    1. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9*8 is prevalent among African–Americans: implications for pharmacogenetic dosing. Pharmacogenomics. 2009;10(8):1243–1255. - PMC - PubMed
    1. Lubitz SA, Scott SA, Rothlauf EB, et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J. Thromb. Haemost. 2010;8(5):1018–1026. - PMC - PubMed
    1. Scott SA, Collet JP, Baber U, et al. Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. Clin. Pharmacol. Ther. 2016;100(3):287–294. - PMC - PubMed

LinkOut - more resources